Taysha Gene Therapies Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon. I'm Salveen Richter Biotechnology analyst at Goldman Sachs, and we're pleased to have with us Taysha. And with us from the company, we have R.A. Session, CEO; Suyash Prasad, Chief Medical Officer and Head of R&D; and Kim Lee, Head of IR. And with that, all right, thanks for joining us.
Questions & Answers
And maybe to level set and start here. Could you remind us of the catalyst path for you. And in 2021, you're clearly focused on neurology diseases within -- with gene therapy and have taken quite a few drugs into the pipeline, and we're looking for first proof-of-concepts. So would love to hear.
Yes, absolutely. And Salveen, thank you guys for having us over at Goldman. I would probably say you guys have the best intro music of the pandemic, just so you know
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |